RU2002129510A - ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-HSP90-АНТИТЕЛАМИ - Google Patents
ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-HSP90-АНТИТЕЛАМИInfo
- Publication number
- RU2002129510A RU2002129510A RU2002129510/15A RU2002129510A RU2002129510A RU 2002129510 A RU2002129510 A RU 2002129510A RU 2002129510/15 A RU2002129510/15 A RU 2002129510/15A RU 2002129510 A RU2002129510 A RU 2002129510A RU 2002129510 A RU2002129510 A RU 2002129510A
- Authority
- RU
- Russia
- Prior art keywords
- antifungal agent
- composition according
- antibody
- fungal
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (11)
1. Применение композиции, включающей антитело или его антигенсвязывающий фрагмент, специфические к одному или более эпитопов грибкового стрессового белка, и противогрибковый агент, включающий по меньшей мере один из группы, состоящей из полиенового противогрибкового агента и эхинокандинового противогрибкового агента, в способе производства лекарственного препарата для лечения грибковых инфекций, где грибок, вызывающий указанную грибковую инфекцию, является резистентным к указанному противогрибковому агенту per se.
2. Применение композиции по п.1, где указанное антитело является специфическим к белку теплового шока для представителей родов Candida или Torulopsis.
3. Применение композиции по п.2, где указанный белок теплового шока включает hsp90 из Candia albicans.
4. Применение композиции по любому из предшествующих пунктов, где указанное антитело или его антигенсвязывающий фрагмент являются специфическими для эпитопа, включающего последовательность SEQ ID NO:l.
5. Применение композиции по п.4, где указанное антитело включает последовательность SEQ ID NO:2.
6. Применение композиции по любому из предшествующих пунктов, где указанный полиеновый противогрибковый агент включает амфотерицин В или производное амфотерицина В.
7. Применение композиции по любому из предшествующих пунктов, где указанный эхинокандиновый противогрибковый агент включает анидулафунгин (LY303366).
8. Применение композиции по любому из предшествующих пунктов, где указанная грибковая инфекция является по меньшей мере одной, выбранной из группы, включающей мукомикоз, бластомикоз, кокцидиоидомикоз или паракокцидоидомикоз, или указанная грибковая инфекция вызвана по меньшей мере одним микроорганизмом, выбранным из группы, состоящей из Candida, Cryptococcus, Histoplasma, Aspergillus или Torulopsis.
9. Применение композиции по п.4 или 5, где указанное антитело или антигенсвязывающий агент помечены детектируемой меткой.
10. Применение композиции по любому из пп.4, 5 или 9, где указанное антитело или антигенсвязывающий фрагмент конъюгированы с молекулой-эффектором.
11. Набор, включающий антитело или его антигенсвязывающий фрагмент, специфические к одному или более эпитопов грибкового стрессового белка, и противогрибковый агент, включающий один из группы, состоящей из полиенового противогрибкового агента и эхинокандинового противогрибкового агента, для применения при лечении грибковых инфекций, где грибок, вызывающий указанную грибковую инфекцию, является резистентным к указанному противогрибковому агенту per se.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0008305.5 | 2000-04-06 | ||
| GBGB0008305.5A GB0008305D0 (en) | 2000-04-06 | 2000-04-06 | Treatment of fungal infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002129510A true RU2002129510A (ru) | 2004-03-27 |
| RU2262952C2 RU2262952C2 (ru) | 2005-10-27 |
Family
ID=9889204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002129510/15A RU2262952C2 (ru) | 2000-04-06 | 2001-03-20 | ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-hsp90-АНТИТЕЛАМИ |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20030180285A1 (ru) |
| EP (4) | EP1852128A1 (ru) |
| JP (1) | JP2003530357A (ru) |
| CN (3) | CN1420786A (ru) |
| AT (1) | ATE364396T1 (ru) |
| AU (2) | AU4089001A (ru) |
| BR (1) | BR0109846A (ru) |
| CA (1) | CA2401836A1 (ru) |
| CY (1) | CY1106794T1 (ru) |
| DE (1) | DE60128893T2 (ru) |
| DK (1) | DK1267925T3 (ru) |
| ES (1) | ES2287105T3 (ru) |
| GB (1) | GB0008305D0 (ru) |
| NO (1) | NO20024815L (ru) |
| NZ (1) | NZ520899A (ru) |
| PL (1) | PL358394A1 (ru) |
| PT (1) | PT1267925E (ru) |
| RU (1) | RU2262952C2 (ru) |
| WO (1) | WO2001076627A1 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050129665A1 (en) * | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
| US7959915B2 (en) | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
| EP1457499A1 (en) * | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| GB0409077D0 (en) | 2004-04-23 | 2004-05-26 | Neutec Pharma Plc | Treatment of fungal infections |
| AU2005259002B2 (en) | 2004-07-02 | 2011-01-27 | Neutec Pharma Limited | Treatment of cancer |
| MX2007000263A (es) * | 2004-07-02 | 2007-07-20 | Neutec Pharma Ltd | Tratamiento de cancer. |
| WO2006091459A2 (en) * | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
| ME01541B (me) * | 2005-04-13 | 2014-04-20 | Astex Therapeutics Ltd | DERIVATI HIDROKSIBENZAMIDA l NJIHOVA PRIMJENA KAO INHIBITORA HSP90 |
| GB0600168D0 (en) * | 2006-01-05 | 2006-02-15 | Neutec Pharma Plc | A therapeutic composition |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2008091692A2 (en) * | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
| US20100111943A1 (en) * | 2007-03-22 | 2010-05-06 | Medical College Of Georgia Research Institute, Inc | Compositions and methods for inhibiting cancer metastasis |
| US20100113355A1 (en) | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| WO2008132174A1 (en) * | 2007-04-27 | 2008-11-06 | Novartis Ag | An immunoglobulin composition |
| US10457726B2 (en) | 2016-06-30 | 2019-10-29 | University Of Connecticut | Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof |
| CN111116743B (zh) * | 2018-10-30 | 2022-01-28 | 迈威(上海)生物科技股份有限公司 | Hsp90抗体及其在抗真菌感染中的应用 |
| CN111679069A (zh) * | 2019-12-31 | 2020-09-18 | 安徽中医药大学 | 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8915019D0 (en) | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
| GB2270076A (en) * | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
| US5834592A (en) * | 1995-09-22 | 1998-11-10 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| US6375955B1 (en) * | 1995-09-22 | 2002-04-23 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| US6365165B1 (en) * | 1995-09-22 | 2002-04-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
-
2000
- 2000-04-06 GB GBGB0008305.5A patent/GB0008305D0/en not_active Ceased
-
2001
- 2001-03-20 BR BR0109846-2A patent/BR0109846A/pt not_active IP Right Cessation
- 2001-03-20 EP EP07075462A patent/EP1852128A1/en not_active Withdrawn
- 2001-03-20 DK DK01911971T patent/DK1267925T3/da active
- 2001-03-20 DE DE60128893T patent/DE60128893T2/de not_active Expired - Lifetime
- 2001-03-20 AT AT01911971T patent/ATE364396T1/de active
- 2001-03-20 EP EP07075188A patent/EP1818062A3/en not_active Withdrawn
- 2001-03-20 JP JP2001574143A patent/JP2003530357A/ja active Pending
- 2001-03-20 NZ NZ520899A patent/NZ520899A/en not_active IP Right Cessation
- 2001-03-20 CN CN01807383A patent/CN1420786A/zh active Pending
- 2001-03-20 CA CA002401836A patent/CA2401836A1/en not_active Abandoned
- 2001-03-20 CN CN200910167220A patent/CN101683525A/zh active Pending
- 2001-03-20 RU RU2002129510/15A patent/RU2262952C2/ru not_active IP Right Cessation
- 2001-03-20 AU AU4089001A patent/AU4089001A/xx active Pending
- 2001-03-20 WO PCT/GB2001/001195 patent/WO2001076627A1/en active IP Right Grant
- 2001-03-20 US US10/240,819 patent/US20030180285A1/en not_active Abandoned
- 2001-03-20 EP EP01911971A patent/EP1267925B8/en not_active Expired - Lifetime
- 2001-03-20 PL PL01358394A patent/PL358394A1/xx not_active Application Discontinuation
- 2001-03-20 EP EP07075857A patent/EP2011512A1/en not_active Withdrawn
- 2001-03-20 ES ES01911971T patent/ES2287105T3/es not_active Expired - Lifetime
- 2001-03-20 AU AU2001240890A patent/AU2001240890B2/en not_active Ceased
- 2001-03-20 PT PT01911971T patent/PT1267925E/pt unknown
- 2001-03-20 CN CNA2007101126651A patent/CN101095952A/zh active Pending
-
2002
- 2002-10-04 NO NO20024815A patent/NO20024815L/no not_active Application Discontinuation
-
2007
- 2007-08-07 CY CY20071101053T patent/CY1106794T1/el unknown
- 2007-11-14 US US11/984,177 patent/US20100285029A1/en not_active Abandoned
-
2008
- 2008-03-20 US US12/076,643 patent/US20080193459A1/en not_active Abandoned
- 2008-03-21 US US12/076,705 patent/US20080181884A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002129510A (ru) | ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-HSP90-АНТИТЕЛАМИ | |
| JP2003530357A5 (ru) | ||
| US8236321B2 (en) | Chemically programmable immunity | |
| ES2540771T3 (es) | Composición de anticuerpos para uso en vacunación contra estafilococos | |
| AR048638A1 (es) | Anticuerpos anti-glicoproteina vi y metodos de los mismos | |
| WO2006041866A3 (en) | Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes | |
| UY28641A1 (es) | Anticuerpos | |
| PT1190257E (pt) | Deteccao precoce dos flavivirus, utilizando a glicoproteina ns1 | |
| JP2008501317A5 (ru) | ||
| KR960022562A (ko) | 항-αV-인터그린 모노크로날 항체 | |
| JP2005501052A5 (ru) | ||
| ES2321351T3 (es) | Compuesto relacionados con apoptosis y su uso. | |
| Cachia et al. | The use of synthetic peptides in the design of a consensus sequence vaccine for Pseudomonas aeruginosa | |
| NZ535908A (en) | HIV regulatory and auxilliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
| BR0214363A (pt) | Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção | |
| WO2004050849A3 (en) | Recombinant immunotoxin and use in treating tumors | |
| US20150093412A1 (en) | Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax | |
| WO1994006464A1 (en) | Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites | |
| WO2004005316A3 (en) | Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes | |
| KR880001815A (ko) | 슈도모나스 에루기노사 편모에 대한 단일클론항체 | |
| WO2004000216A3 (en) | Anti-tenascin antibody fragments and minibodies for treatment of lymphoma | |
| JP2008531719A5 (ru) | ||
| DE60136221D1 (de) | Lymphombehandlung mit dem monoklonalen anti-tenascin-antikörper | |
| TNSN06339A1 (en) | Treatment of fungal infections | |
| JP2004502782A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120321 |